TOP CONTRIBUTORS

Tom Park

www.zacks.com

HSP AT A GLANCE

P/E ► 18.0 HIGH EV/EBITDA ► 13.6 HIGH ROA ► 9.8% AVG ROE ► 19% AVG Debt to Equity ► 1.30 AVG Current Ratio ► 2.27 AVG Interest Coverage Ratio ► 4.65 AVG

 

 

 

 

 

 

Hospira is a global specialty pharmaceutical and medication delivery company that is focused on products that improve the safety and efficacy of patient care in the acute care setting. Hospira is a global leader in the development, manufacture, and marketing of specialty injectable pharmaceuticals and medication delivery systems that deliver drugs and intravenous (I.V.) fluids. Hospira is also a leading provider of contract manufacturing services to pharmaceutical and biotechnology companies for formulation development and filling and finishing of injectable pharmaceuticals. Hospira's U.S. product line is based on five categories: Specialty Injectable Pharmaceuticals, Medication Delivery Systems, Injectable Pharmaceutical Contract Manufacturing, Sales to Abbott, and Other. Other includes sales to non-hospital customers and sales of critical care products. Specialty Injectable Pharmaceuticals and Medication Delivery Systems generate the majority of Hospira's base revenue. Hospitals, alternate site clinics, home healthcare providers, and long-term care facilities use Hospira's broad portfolio of products. Based on 2006 results, U.S. sales and international sales contributed 83% and 17%, respectively, to total sales. In the U.S. market, Specialty Injectable Pharmaceuticals, Medication Delivery Systems, Contract Manufacturing, Sales to Abbott, and Other contributed 30%, 32%, 7%, 3%, and 11%, respectively, to total sales in 2006. In the international market, Sales to Third Parties and Sales to Abbott contributed 15% and 2%, respectively, to total sales in 2006.

References